Nephron Research upgraded Revvity (RVTY) to Hold from Sell with a $90 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity’s AI Push Brings Innovation Potential but Heightened Operational, Legal, and Reputational Risks
- Revvity price target raised to $129 from $123 at Baird
- Revvity price target raised to $124 from $120 at TD Cowen
- Revvity price target raised to $118 from $112 at Evercore ISI
- Revvity price target raised to $118 from $115 at Barclays